INDSWFTLABNSEInd-Swift Laboratories Limited· PharmaceuticalsHighNeutral
Announced Wed, 22 Apr · 15:43 IST

Disclosures under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011

Ownership Changes View source PDF

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.4%1-day move
₹142.50
prior close
₹142.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.1-0.5-0.6-4.4-5.4-2.5-4.5-3.2+0.4-4.6-6.9+35.4+57.9
Up moveDown movePending
AI summary

HCP Investments, a Mauritius-based investment entity, sold 6,503,423 equity shares (7.5%) of Ind-Swift Laboratories Limited in the open market between April 13-17, 2026. Before the sale, HCP held 7,500,000 shares (8.649% of share capital). After completing the disposal, their remaining holding is 996,577 shares (1.149%). HCP Investments is not a promoter or person acting in concert with any promoter of the company. The sale was executed in multiple tranches across the specified dates.

Likely market impact

This represents a significant exit by a substantial shareholder, reducing their stake from 8.65% to just 1.15%. The open market sale of such a large block (7.5%) could exert downward pressure on the stock price in the near term, as it signals reduced institutional backing from this investor.